Diane-Laure Pagés
Co-founder & COO
at
Orakl Oncology

Diane-Laure Pagès is the co-founder and COO of Orakl Oncology, a French techbio company building an AI-native platform that predicts how cancer drugs will perform in patients. Orakl spun out of Gustave Roussy, one of Europe’s leading cancer centres, in 2023. It combines tumour avatars grown from patient samples with clinical data and machine learning, so that drug developers can de-risk their programmes. As COO, Diane-Laure runs operations, legal and people, and leads the hospital partnerships that give Orakl access to patient tumour samples and matched clinical data. An engineer by training, she is a graduate of École polytechnique and holds a PhD in biology from Gustave Roussy. Orakl raised €11M in December 2024 to launch its first products, O-Predict and O-Validate.